Search results for " ondansetron"

showing 2 items of 2 documents

Efficacy of Three Different Prophylactic Treatments for Postoperative Nausea and Vomiting after Vitrectomy: A Randomized Clinical Trial

2019

Postoperative nausea and vomiting (PONV) after vitreoretinal surgery may potentially be associated with severe complications, such as suprachoroidal hemorrhage. The purpose of the present multicenter clinical trial (NCT02386059) was to assess the efficacy of three different prophylactic treatments for PONV after vitrectomy under local anesthesia. Patients undergoing primary vitrectomy were randomized to the control arm or to one of the treatment arms (4 mg ondansetron, 4 mg dexamethasone, combination of the two drugs). The primary outcome measure was the proportion of complete response (no nausea, no vomiting, no retching, and no use of antiemetic rescue medication) during 24 h after vitrec…

Nauseamedicine.drug_classvitrectomylcsh:Medicinepostoperative nausea and vomitingdexamethasoneArticlelaw.inventionOndansetron03 medical and health sciences0302 clinical medicineRandomized controlled trial030202 anesthesiologylawmedicineAntiemeticRetchingLocal anesthesiabusiness.industrylcsh:RGeneral MedicineondansetronAnesthesia030221 ophthalmology & optometryVomitingdexamethasone; ondansetron; postoperative nausea and vomiting; vitrectomymedicine.symptombusinessPostoperative nausea and vomitingmedicine.drug
researchProduct

NEPA as antiemetic prophylaxis after failure of 5HT3-RA plus dexamethasone in patients receiving carboplatin and gemcitabine chemotherapy: A monocent…

2020

Introduction Chemotherapy-induced nausea and vomiting (CINV) may affect adherence to planned chemotherapy treatments and compromise patients’ quality of life during the therapy. NEPA is an oral fixed combination of netupitant, a highly-selective NK1-RA and palonosetron, a 5HT3-RA, approved for the prevention of acute and delayed CINV. The aim of this study was to evaluate the efficacy and safety of NEPA with dexamethasone for CINV prophylaxis in the challenging setting of carboplatin and gemcitabine combination chemotherapy, after failure of prophylaxis with 5HT3 receptor antagonist. Methods Eligible patients were undergoing carboplatin and gemcitabine combination chemotherapy for metastati…

0301 basic medicineOncologymedicine.medical_specialtyNauseamedicine.drug_classmedicine.medical_treatmentOndansetron03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineAntiemeticPharmacology (medical)carboplatin Chemotherapy-induced nausea and vomiting gemcitabine netupitant NSCLC ondansetron ovarian cancer palonosetron urothelial cancer dexamethasoneChemotherapybusiness.industryGemcitabineCarboplatin030104 developmental biologyOncologychemistry030220 oncology & carcinogenesisVomitingmedicine.symptombusinessmedicine.drugChemotherapy-induced nausea and vomiting
researchProduct